Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YAT2150
- Development stage
- Preclinical
- Lead developer
- Institute for Bioengineering of Catalonia
- Modality
- Small Molecules
01
Overview
YAT2150 is a bis(styrylpyridinium) salt and a protein aggregation inhibitor that acts as a potent antimalarial and antileishmanial agent. It is also the active component of the commercial ProteoStat reagent used to stain protein deposits in living cells. YAT2150 exhibits significant antiplasmodial activity against *Plasmodium falciparum* (including chloroquine- and artemisinin-resistant strains) and *Plasmodium vivax*, as well as antileishmanial activity against *Leishmania infantum*. Its mechanism of action involves binding to and inhibiting the formation of biomolecular condensates and protein aggregates, thereby disrupting proteostasis in the parasite.
- Brand names
- ProteoStat
- Other names
- bis(styrylpyridinium) salt YAT2150styrylpyridinium salt YAT2150
Beyond the preview
Go deeper on YAT2150.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YAT2150.